Enhancement of CCL2 expression and monocyte migration by CCN1 in osteoblasts through inhibiting miR-518a-5p: implication of rheumatoid arthritis therapy

Cheng-Yu Chen¹, Lih-Jyh Fuh², Chien-Chung Huang³, Chin-Jung Hsu⁴,⁵, Chen-Ming Su⁶, Shan-Chi Liu¹, Yu-Min Lin⁷,⁸ & Chih-Hsin Tang¹,⁹,¹⁰

Cysteine-rich 61 (Cyr61 or CCN1), a secreted protein from the CCN family, is an important proinflammatory cytokine. Migration and infiltration of mononuclear cells to inflammatory sites play a critical role in the pathogenesis of rheumatoid arthritis (RA). Monocyte chemoattractant protein-1 (MCP-1/CCL2) is the key chemokine that regulates migration and infiltration of monocytes. Here, we examined the role of CCN1 in monocyte migration, and CCL2 expression in osteoblasts. We found higher levels of CCN1 and CCL2 in synovial fluid from RA patients compared with levels from non-RA controls. We also found that the CCN1-induced increase in CCL2 expression is mediated by the MAPK signaling pathway and that miR-518a-5p expression was negatively regulated by CCN1 via the MAPK cascade. In contrast, inhibition of CCN1 expression with lentiviral vectors expressing short hairpin RNA ameliorated articular swelling, cartilage erosion, and infiltration of monocytes in the ankle joints of mice with collagen-induced arthritis. Our study describes how CCN1 promotes monocyte migration by upregulating CCL2 expression in osteoblasts in RA disease. CCN1 could serve as a potential target for RA treatment.

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disorder, in which the immune system attacks the healthy lining of joints. Pathological features of RA include inflammation, synovial swelling, pannus formation, stiffness in the joints and articular cartilage destruction. Most RA research has focused on cartilage destruction and synovial membrane inflammation. Recent reports have examined the involvement of subchondral bone erosions in RA pathogenesis. Recent reports have indicated that subchondral bone plays a crucial role in cartilage pathology during the progression of RA. Therefore, better treatment strategies will ultimately require an improved understanding of the molecular mechanisms in subchondral bone in RA pathogenesis.

Accumulating evidence indicates that mononuclear cell migration plays an important step in the perpetuation of inflammation in RA. Monocyte chemoattractant protein-1 (MCP-1), also known as chemokine ligand 2 (CCL2), belongs to the CC chemokine family. CCL2 is one of the key factors involved in the initiation of inflammation. It triggers chemotaxis and transendothelial migration of monocytes to inflammatory lesions. CCL2 has been implicated in the pathophysiology of several inflammatory conditions including atherosclerosis, multiple...
sclerosis, arthritis and various cancers, via the attraction of monocytes and lymphocytes to the site of inflammation\(^{31}\). In addition, CCL2 levels are increased in the blood, synovial fluid, and synovial tissue of patients with RA compared with non-RA controls\(^{13,14}\). Injection of CCL2 into rabbit joints resulted in marked macrophage infiltration in the affected joint\(^{14}\) and other preclinical evidence indicates that overexpression of CCL2 induces synovitis\(^{31}\), suggesting that CCL2 is a key regulator in monocyte migration and the inflammatory response during RA pathogenesis.

Cysteine-rich protein 61 (Cyr61/CCN1) is a component of the extracellular matrix and plays a role in endothelial cell adhesion, migration, proliferation, and differentiation\(^{18}\). Recently, it has been discovered that CCN1 promotes inflammation and regulates the effects of cytokines in chronic disease\(^{37}\). Moreover, CCN1 was necessary for interleukin-17 (IL-17)-induced fibroblast-like synoviocytes proliferation\(^{18}\) and promotes proinflammatory cytokine IL-1\(\beta\) production during the progression of RA disease\(^{19}\), and enhances VEGF-A-dependent angiogenesis in RA process\(^{38}\). These reports suggest that CCN1 plays a critical role in the pathogenesis of RA.

CCL2 is a chief regulator of monocyte infiltration in RA, which is constitutively expressed in the subchondral bone and may be associated with osteoblasts\(^{41}\). Although it is recognized that CCN1 is involved in RA pathogenesis, the role of CCN1 in CCL2 expression and monocyte accumulation is unclear. Our study results show that CCN1 induces upregulation of CCL2 expression in osteoblasts and subsequently promotes monocyte migration. In addition, in vitro results from our study show that lentiviral knockdown of CCN1 significantly abolishes bone erosion and monocyte infiltration in joints of mice with collagen-induced arthritis (CIA). These results provide new insights into the mechanisms of CCN1 action that may have therapeutic implications for patients with RA.

**Results**

**High levels of CCN1 and CCL2 expression in RA synovial fluid.** CCN1 promotes the production of inflammatory cytokines such as IL-6 and oncostatin M (OSM) during the RA disease process\(^{37,22}\). To characterize the role of CCN1 in CCL2 expression and monocyte infiltration during RA, we first analyzed CCN1 and CCL2 expression profiles in RA patients. We found that levels of CCN1 and CCL2 were significantly higher in synovial fluid from patients with RA compared with those from non-RA patients (Fig. 1A and B). The quantitative data also showed a highly positive correlation between the expression of CCN1 and CCL2 in RA patients (Fig. 1C). These results indicate that CCN1 and CCL2 levels are elevated in RA synovial fluid. We then examined whether CCN1 and CCL2 in RA synovial fluid enhance monocyte infiltration. An in vitro chemotaxis assay revealed monocyte migration in response to RA synovial fluid, which was attenuated by pre-incubation for 30 min with an anti-CCL2 neutralizing antibody; no such effect was seen with anti-CCN1 neutralizing antibody (Fig. 1D), implying that CCL2 is an important factor in monocyte infiltration during RA. Next, we examined whether CCN1 regulates CCL2-mediated monocyte migration in RA disease.

**CCN1 promotes CCL2 expression and enhances monocyte migration in osteoblasts.** Emerging evidence indicates that subchondral bone plays an essential role in the mechanisms of bone remodeling during the development of RA\(^{33}\). We examined CCL2 production in osteoblasts after CCN1 treatment. Treatment of osteoblasts (MG63 and hFOB cells) increased CCL2 mRNA expression and protein secretion in a concentration-dependent manner (Fig. 2A–F). In addition, conditioned medium (CM) from CCN1-treated osteoblasts dramatically enhanced monocyte migration and this effect was blocked by a CCL2 mAb (Fig. 2G–J), which implies that CCN1 promotes monocyte migration through a CCL2-dependent pathway. Integrin \(\alpha\)\(\beta\)3 has been implicated in CCN1-induced OSM expression in osteoblasts\(^{42}\). We found that treatment of osteoblasts with \(\alpha\)\(\beta\)3 integrin mAb abolished CCN1-induced CCL2 expression (Supplementary Fig. S1), demonstrating that integrin \(\alpha\)\(\beta\)3 is involved in CCN1-induced promotion of CCL2 expression.

**CCN1 promotes CCL2 expression and monocyte migration through the MAPK pathway.** Mitogen-activated protein kinases (MAPKs) ERK, JNK, and p38 MAPK are involved in the regulation of CCL2 expression\(^{24,25}\). We therefore investigated the role of MAPKs in mediating CCN1-induced CCL2 expression, using the specific p38 inhibitor SB203580, JNK inhibitor SP600125, and MEK1/2 inhibitor U0126. Pretreatment of osteoblasts with these agents reversed CCN1-induced CCL2 expression (Fig. 3A–C). The quantitative data also showed a highly positive correlation between the expression of CCN1 and CCL2 in RA patients (Fig. 1C). These results indicate that CCN1 and CCL2 levels are elevated in RA synovial fluid. We then examined whether CCN1 and CCL2 in RA synovial fluid enhance monocyte infiltration. An in vitro chemotaxis assay revealed monocyte migration in response to RA synovial fluid, which was attenuated by pre-incubation for 30 min with an anti-CCL2 neutralizing antibody; no such effect was seen with anti-CCN1 neutralizing antibody (Fig. 1D), implying that CCL2 is an important factor in monocyte infiltration during RA. Next, we examined whether CCN1 regulates CCL2-mediated monocyte migration in RA disease.

**CCN1 promotes CCL2 expression via inhibition of miR-518a-5p expression.** miRNAs are important regulators in RA, which makes them promising therapeutic targets\(^{26}\). Open-source software (TargetScan, miRDB, and PicTar) was used to predict and identify target miRNAs. These tools revealed that the 3′UTR region of CCL2 mRNA harbors potential binding sites for miR-518a-5p. Exogenous CCN1 reduced miR-518a-5p expression in a concentration-dependent manner (Fig. 4A). We found that transfection of osteoblasts with the miR-518a-5p mimic reduced CCN1-induced CCL2 expression (Fig. 4B–D) and reduced CCN1-promoted monocyte migration (Fig. 4E). Thus, CCN1 promotes CCL2 expression and monocyte migration by suppressing miR-518a-5p expression.

To learn whether miR-518a-5p regulates the 3′UTR region of CCL2, we constructed a luciferase reporter vector harboring the wild-type (wt-CCL2-3′UTR) or mutant (mt-CCL2-3′UTR) 3′UTR region of CCL2 mRNA (Fig. 4F). The results show that CCN1 increased wild-type but not mutant CCL2 3′UTR luciferase activity (Fig. 4G). Transfection with miR-518a-5p mimic inhibited CCN1-induced wild-type CCL2-3′UTR luciferase activity (Fig. 4G), while treatment with U0126, SB203580, and SP600125 reversed CCN1-inhibited miR-518a-5p
expression (Fig. 4H). These data suggest that miR-518a-5p directly represses CCL2 protein expression via binding to the 3′ UTR region of the human CCL2 gene through MAPK signaling.

Knockdown of CCN1 impairs CIA-induced RA and monocyte infiltration. To confirm CCN1-mediated CCL2 expression and monocyte infiltration in vivo, CCN1-shRNA was transfected into osteoblasts, thus reducing CCN1 and CCL2 expression (Fig. 5A). Next, we used the CIA model to investigate whether the knockdown of CCN1 was able to inhibit arthritis in vivo. Within 4 weeks, mice had a very high incidence of arthritis, and 95% of animals developed severe arthritis. Mice injected with Lenti-shCCN1 had significantly attenuated paw swelling compared with the control group, as reflected by hind paw volume data (Fig. 5B). Micro-computed tomography (micro-CT) imaging of hind paws showed that bone erosion was significantly increased in the CIA mice (Fig. 5C), whereas Lenti-shCCN1-infected had lower levels of bone erosion compared with controls (Fig. 5C). Intra-articular cartilage erosion and proteoglycan content were assayed by staining with H&E and safranin O (Fig. 5D). IHC staining of the ankle joints revealed that the number of CD68- (monocytes/macrophages marker) and CCL2-positive cells were significantly increased in mice with CIA but markedly diminished in CIA mice treated with Lenti-shCCN1 (Fig. 5D). Our results confirmed that Lenti-shCCN1 prevents cartilage erosion and reduces monocyte infiltration in vivo.

Discussion

RA is a systemic immune disease that causes chronic inflammation of the synovium and bone destruction in the joint. The inflammatory process is mediated through a complex cytokine and chemokine. It is not well understood as to which factors are responsible for initiating the degradation and loss of the articular tissues. CCL2 is believed to play an important role as a proinflammatory agent and assist in the accumulation of leucocytes and monocytes in RA synovial and fluid, increasing the intensity of synovial inflammation37,38. CCN1 is involved in RA pathogenesis39; its effect on CCL2 expression and monocyte infiltration is largely unknown. CCN1 has been reported to promote CCL2 production in endothelial cells and endothelial progenitor cells40. This current study found significantly
higher levels of CCN1 and CCL2 expression in RA synovial fluid compared with non-RA synovial fluid. Moreover, we identified CCL2 as a target protein for the CCN1 signaling pathway regulating monocyte infiltration. Treatment of osteoblasts with CCN1 increased CCL2 expression, inducing the migration of human monocytes. CM-mediated monocyte migration in osteoblasts was abolished by CCL2 mAb treatment. In addition, CCN1 knockdown reduced CIA-induced RA and monocyte infiltration. Our data suggest that CCN1 increases CCL2 expression and promotes monocyte migration in osteoblasts. This phenomenon may occur via inhibition of miR-518a-5p through the MAPK signaling pathway. We previously reported that CCN1 promotes VEGF-A expression in osteoblasts and subsequently enhances angiogenesis through the inhibition of miR-216 during RA disease. Lin et al., have also indicated that CCN1 induces proinflammatory cytokine IL-6 production in RA synovial fibroblasts. Furthermore, CCN1 has

Figure 2. CCN1 promotes CCL2-dependent monocyte migration. (A–F) MG63 and hFOB cells were incubated with various concentrations of CCN1 (0–3 ng/ml) for 24 h; CCL2 expression was examined by qPCR, ELISA, and Western blot analysis (n = 5 per group). (G and H) Osteoblasts were incubated with CCN1 (0–3 ng/ml) for 24 h, or pretreated for 30 min with IgG control antibody or CCL2 antibody, followed by stimulation with CCN1 (3 ng/ml) for 24 h. Medium was collected as CM and THP-1 migration was assessed by in vitro chemotaxis assay (n = 5 per group). Results are expressed as the mean ± S.E. *p < 0.05 compared with controls.
Figure 3. The MAPK signaling pathway is involved in CCN1-induced CCL2 expression. (A–E) MG63 cells were pretreated with SB203580 (10 μM), SP600125 (3 μM), or U0126 (10 μM) for 30 min, or transfected with ERK, JNK, and p38 siRNA for 24 h, followed by stimulation with CCN1 for 24 h. CCL2 expression was examined by qPCR, ELISA and Western blot analysis (n = 5 per group). (F) Medium was collected as CM, and THP-1 migration was assessed by in vitro chemotaxis assay (n = 5 per group). (G) MG63 cells were incubated with CCN1 (3 ng/ml) for indicated time intervals, and ERK, JNK, and p38 phosphorylation was examined by Western blot analysis (n = 4). Results are expressed as the mean ± S.E. *p < 0.05 compared with controls. †p < 0.05 compared with CCN1-treated group.
Figure 4. CCN1 promotes CCL2 expression and monocyte migration via inhibition of miR-518a-5p. (A) MG63 cells were incubated with CCN1 (1–3 ng/ml) for 24 h; miR-518a-5p expression was examined by qPCR (n = 5 per group). (B–D) MG63 cells were transfected with control miRNA or miR-518a-5p mimic for 24 h followed by stimulation with CCN1 for 24 h, and CCL2 expression was examined by qPCR, ELISA and Western blot analysis (n = 5 per group). (E) Medium was collected as CM and THP-1 migration was assessed by in vitro chemotaxis assay (n = 5 per group). (F) Schematic 3′UTR representation of the human CCL2 containing the miR-518a-5p binding site. (G) MG63 cells were transfected with wt-CCL2-3′UTR or mt-CCL2-3′UTR plasmid for 24 h and stimulated with CCN1 for 24 h; relative luciferase/renilla activities were measured as described in the Methods section (n = 4 per group). (H) MG63 cells were pretreated with SB203580, SP600125, and U0126 for 30 min followed by stimulation with CCN1 for 24 h, and miR-518a-5p expression was examined by qPCR (n = 5 per group). Results are expressed as the mean ± S.E. *p < 0.05 compared with controls. **p < 0.05 compared with CCN1-treated group.
Figure 5. Lenti-shCCN1 attenuates bone erosion and monocyte migration in CIA mice. (A) CCN1 and CCL2 expression in control-shRNA MG63 and CCN1-shRNA MG63 cells was examined by Western blot analysis (n = 4). (B) The control and CIA mice were administered intra-articular injections of 7.1 × 10^6 PFU Lenti-shCCN1 on day 14 and sacrificed on day 42. Swelling of hind paws was measured by a digital plethysmometer (n = 5 per group). (C) Representative micro-CT images of the hind paws on day 42. (D) Histologic sections of ankle joints were stained with H&E or safranin O and immunostained with CCL2 or CD68; Scale bar, 50 μm. Results are expressed as the mean ± S.E. *p < 0.05 compared with controls. #p < 0.05 compared with CCN1-treated group.
been reported to induce other proinflammatory cytokines such as IL-1β and IL-17, as well as OSM expression during RA 17, 18. Our current results and previous findings suggest that CCN1 is a key regulator in RA and may serve as a therapeutic target in treatment using a small molecule inhibitor or CCN1 antibody.

CCN1 has been implicated in other autoimmune/inflammatory diseases besides RA. For instance, CCN1 can aggravate psoriasis 32 and also enhance the pathogenesis of psoriasis through up-regulation of IL-8 33. Conversely, other evidence indicates that CCN1 modulates the course of colitis 43 through IL-6 46. Furthermore, overexpression of CCN1 exacerbates obliterative bronchiolitis in mice 46. Cigarette smoke extract-induced CCN1 augments IL-8, VEGF and MMP expression in bronchial epithelial cells 37, 38. This current study indicated that CCN1 mediates arthritis pathogenesis and supports the previous evidence suggesting that CCN1 plays a critical role in autoimmune/inflammatory diseases.

Studies have increasingly focused on the impact of inflammation in osteoblasts, which exhibit important functions within the arthritic bone microenvironment and RA pathogenesis 39, 40. These studies highlight that the influence of inflammation on bone is specific to the site of inflammation and dependent upon the cytokines present within the local bone microenvironment 39, 40. CCL2 is constitutively expressed in the subchondral bone and associated with osteoblasts in RA 41. Our results support these concepts and we found that CCN1 promotes osteoblast production of CCL2 and subsequently induces monocyte migration. Knockdown CCN1 inhibited CIA-induced RA and monocytes/macrophages marker expression in subchondral bone in vivo. Our results provide evidence that osteoblast-mediated monocyte migration plays a crucial role during the arthritis disease process. In this study, we did not perform shRNA-control in CIA mice. However, intra-articular injected shCCN1 did not affect the paw swelling, cartilage degradation and bone erosion in mice. In addition, previous studies indicated that Lenti-negative control shRNA didn't have any effects when compared with the CIA group 41–43. Therefore, the Lentivirus delivery effect can be rule out.

Evidence indicates that the MAPK signaling pathway plays an important role in the regulation of gene expression levels 44. Here, we report that the MEK1/2 inhibitor U0126, p38 inhibitor SB203580, and JNK inhibitor SP600125 antagonized CCN1-induced CCL2 expression. Conversely, these inhibitors blocked CCN1-promoted monocyte migration. In this study, incubation of osteoblastic cells with CCN1 promoted ERK, p38, and JNK phosphorylation, suggesting that MAPK activation plays a key role in CCN1-induced CCL2 production and monocyte infiltration.

Several studies have focused on the role of miRNAs in gene regulation 45. As miRNAs are able to modulate target gene translation via binding to the 3′-UTR of mRNAs and thus affect multiple protein-encoding genes at the post-transcriptional level, they are implicated in the control of a wide range of biological functions 46. Therefore, we investigated whether miRNAs are involved in monocyte migration following CCN1 stimulation. The current study showed that CCN1 markedly represses miR-518a-5p expression in osteoblasts. Co-transfection of cells with miR-518a-5p mimic abolished CCN1-induced CCL2 expression and monocyte migration. Strikingly, we found that miR-518a-5p directly inhibited CCL2 protein expression through binding to the 3′UTR of the human CCL2 gene, thereby negatively regulating CCL2-mediated monocyte migration. These findings provide insight into potential miRNA-based strategies for CCL2-mediated monocyte migration.

In conclusion, our study has identified that CCN1 promotes CCL2 expression in osteoblasts through the negative regulation of miR-518a-5p via the MAPK signaling pathway, leading to the depletion of monocyte infiltration. CCN1 may be a novel therapeutic target in RA.

**Materials and Methods**

**Materials.** Rabbit polyclonal antibodies specific for β-actin, CCL2, p-ERK, ERK, p-p38, p38, p-JNK, JNK, and CD68 were purchased from Santa Cruz Biotecnoogy (Santa Cruz, CA). Mouse monoclonal antibody specific for CCN1 was purchased from R&D Systems (Minneapolis, MN). Recombinant human CCN1 was purchased from PeproTech (Rocky Hill, NJ). Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), and all other cell culture reagents were purchased from Gibco-BRL Life Technologies (Grand Island, NY). The dual-luciferase reporter assay kit was purchased from Promega (Madison, WI, USA). Negative control miRNA and human miR-518a-5p mimic were purchased from GeneDireX (Las Vegas, NV). All chemicals were purchased from Sigma-Aldrich (St. Louis, MO).

**Cell culture.** The human osteoblast-like cell line MG63 and conditionally immortalized human fetal osteoblastic cell line hFOB were purchased from American Type Culture Collection (Manassas, VA). MG63 cells were cultured in MEM supplemented with 10% FBS and antibiotics (100 U/ml of penicillin and 100 μg/ml of streptomycin) and were maintained at 37°C in a humidified atmosphere of 5% CO2. hFOB cells were cultured in a 1:1 mixture of phenol-free DMEM/Ham's F12 medium containing 10% FBS supplemented with antibiotics at 33.5°C, the optimal temperature for rapid proliferation of the large T antigen from the Simian Virus (SV40).

THP-1, a human leukemia cell line of monocyte/macrophage lineage, was obtained from American Type Culture Collection (Manassas, VA, USA) and grown in RPMI-1640 medium with 10% FBS 47, 48. Human synovial fluids. We obtained study approval from the local ethics committee and all participants gave written informed consent before study enrolment. Synovial fluid was obtained from 6 RA patients undergoing total knee arthroplasty; non-RA synovial fluid was obtained from 4 patients during arthroscopy for trauma/joint derangement. The China Medical University Hospital Institutional Review Board approved the protocol, and all methods were carried out in accordance with the guidelines and regulations promulgated by the Hospital's Institutional Review Board.

**Quantification of mRNA and miRNA by real-time quantitative polymerase chain reaction amplification.** Total RNA was extracted from osteoblasts using a TRizol® kit (MDBio, Taipei, Taiwan) and miRNAs were quantified using the Mir-X™ miRNA First-Strand Synthesis Kit (Clontech Laboratories, Palo Alto, CA) and an ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). The Mir-X™ miRNA First-Strand Synthesis Kit was used to convert miRNAs to complementary DNA (cDNA) using a specific miRNA oligo-dT primer. The cDNA was then used as a template for qRT-PCR using the ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). The primers were designed using BioEdit (Ibis Biosciences, CA) and the CCL2 primers were as follows: forward, 5′-CGGATCAAGAGAGGGCTAC-3′; reverse, 5′-GGCTCCCTCCCTCTCGTCT-3′. The primers were synthesized by Bioneer (Daejeon, South Korea). The qRT-PCR reactions were performed using the CFX96 real-time PCR detection system (Bio-Rad, Hercules, CA) in 96-well microplates with 20 μl of 2x Sybr Green master mix (Bio-Rad, Hercules, CA). The expression of CCL2 was normalized to the expression of 18S rRNA. The fold change in expression was calculated using the 2−ΔΔCT method.
Alto, CA), as per the manufacturers’ protocols. RNA quality and total RNA samples were examined using the Nanovue+ Spectrophotometer (GE Healthcare, WI). Complementary DNA was derived from 1 μg of total RNA using an M-MLV Reverse Transcriptase kit (Invitrogen, Carlsbad, CA), according to the manufacturer’s recommendations. Real-time quantitative polymerase chain reaction (qPCR) analysis was carried out with the KAPA SYBR® FAST qPCR Kit (Applied Biosystems, Foster City, CA). Relative normalization of gene expression was performed using endogenous GAPDH as the internal control for mRNA or small nuclear RNA U6 as the internal control for micro RNA (miRNA).

Western blot analysis. Cellular lysates were prepared as according to our previous instructions49. Proteins were resolved under SDS-PAGE conditions, then transferred electrophoretically onto polyvinylidene fluoride (PVDF) membranes (Immobilon, Bedford, MA). Blots were blocked with 4% BSA for 1 h at room temperature, then probed with primary antibodies against CCL2, p-ERK, ERK, p-p38, p38, p-JNK, JNK (1:1000) and β-actin (1:2000) for another hour at room temperature. After three washes, blots were subsequently incubated with the horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature and visualized by enhanced chemiluminescence using ImageQuant™ LAS 4000 (GE Healthcare, Prewaukee, WI).

Enzyme-linked immunosorbent assay (ELISA). Osteoblasts were cultured in 24-well plates until they reached 90% confluence and were then changed to serum-free medium, in which they were treated with CCN1 alone for 24 h or pretreated with pharmacological inhibitors, followed by 24 h of CCN1 stimulation. CM was collected, centrifuged and stored at −80 °C. CCL2 levels were assessed in the culture media using the CCL2 ELISA kit (R&D Systems; Minneapolis, MN), as per the manufacturer’s protocol.

In vitro chemotaxis assay. Synovial fluid or CM obtained from cells treated with CCN1 or pharmacological inhibitors were placed in the lower compartment of Transwell cluster plates (Costa Corning, Cambridge, MA, USA); the two-compartment chambers were separated by a polycarbonate membrane filter. TPH-1 cells (5 × 10⁶ cells) were added to the upper chamber and incubated at 37 °C for 4 h, then fixed in 3.7% formaldehyde for 5 min and stained with 0.05% crystal violet in phosphate-buffered saline (PBS) for 15 min. Cells on the upper side of the filters were removed with cotton-tipped swabs and the filters were washed with PBS. Cells on the underside of the filters were examined and counted under a microscope. A goat anti-mouse CCL2 or goat IgG was used in the chemotaxis assay media to determine the biological specificity of the above chemokines produced by the cells to stimulate monocyte migration.

Plasmid construction. The 3′-untranslated region (3′UTR) of human CCL2 contains a miR-518a-5p binding site. A DNA fragment containing wt-CCL2 3′UTR (CCL2 3′-UTR) and mt-CCL2 3′UTR were purchased from Invitrogen. The fragment from 84~277 of CCL2 3′-UTR was subcloned into the luciferase reporter vector pmirGLO-control (Promega, Madison, WI), upstream of the vector’s promoter. The construct was confirmed by sequencing with the Applied Biosystems 3730xl DNA Analyzer (Thermo Fisher Scientific, NY).

CCN1 knockdown in osteoblast cell lines. Recombinant lentiviruses were produced by transient co-transfection of 293 T cells with short hairpin (sh)RNA-expressing plasmid (TRCN0000118099) along with the packaging plasmid pCMVΔR8.91 and the VSV-G envelope glycoprotein expression plasmid pMD.G, all of which were obtained from the National RNAi Core Facility at the Academia Sinica in Taiwan. After 48 h, lentiviral particles carrying CCN1 shRNA (shCCN1) were isolated from the supernatant of 293 T cells. A plaque assay using serial dilution was performed in human osteoblasts to determine virus titers (in plaque-forming units [PFU]) of shCCN1. The viral titer of shCCN1 was determined to be ~7.1 × 10⁹ PFU.

Osteoblasts were seeded in 6 cm plates for 24 h. Growth media was removed and replaced with fresh media containing polybrene (5 μg/ml). Cells were infected by addition of shCCN1 particles to the culture. After incubation overnight, the media was removed and replaced with 5 ml of fresh growth media containing 2 μg/ml puromycin, to select for stable transfecants. Single clones were picked, and the ectopic expression of the gene of interest was verified using Western blot analysis.

Collagen-induced arthritis mouse model. All animal procedures were approved and performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of China Medical University. 20 Male C57BL/6 mice (aged 8~10 weeks, body weight 25 ± 3 g) were purchased from the National Laboratory Animal Centre (Taipei, Taiwan) and randomized to four groups: Control group, healthy mice; CIA + shCCN1 group, CIA-induced arthritis treated with shCCN1; shCCN1 group, healthy mice treated with shCCN1. The CIA mouse model protocol followed that detailed in previously published work50, 51. First, 0.1 ml of an emulsion containing 100 mg of bovine type II collagen (CII) dissolved at a concentration of 2 mg/ml in 0.1 M acetic acid and complete Freund’s adjuvant was injected intradermally into the base of the tail. Two weeks after the primary immunization, a booster injection of 100 μg CII dissolved and emulsified 1:1 with incomplete Freund’s adjuvant was administered into the hind paw. The incidence of arthritis in CIA mice was very high within 6 weeks after the first immunization, and 95% of the mice developed severe arthritis.

The control and CIA mice were administered intra-articular injections of 7.1 × 10⁹ PFU Lenti-shCCN1 on day 14 and sacrificed on day 42. The severity of arthritis in each paw was measured in a blinded manner with a plethysmometer (Marsap, Mumbai, India) once weekly for 4 weeks. Upon sacrifice on day 42, phalanges and ankle joints were removed immediately and fixed in 4% paraformaldehyde for micro-CT analysis. For bone erosion analysis, the reconstructed images of tarsal bone and metatarsal bone were isolated. In brief, all individual samples were re-oriented to the same position and ankle using Dataviewer (SkyScan). 690 slices (2.0 mm) from the edge of tarsal...
bone were selected as the region of interest, as this area included tarsal bone and parts of metatarsal bone; CTAn software (SkyScan) was used to calculate the threshold value and morphometric indices of bone. For illustration, density rendering software CTVox (Version 3.0, SkyScan) was used to provide 3D images and all individual samples used the same color and lighting/shadow visualization.

**IHC (immunohistochemistry) staining.** Paraffin-embedded sections were prepared, mounted on silane-coated slides, deparaffinized in xylene, rehydrated in a graded alcohol series and rinsed in deionized water. After antigen retrieval, intrinsic peroxidase activity was blocked by incubation with 3% H2O2. Non-specific antibody-binding sites were blocked using 3% BSA in PBS. Sections were then incubated with appropriately diluted primary antibodies specific for mouse CD68 or CCL2 at 4°C overnight. After three washes in PBS, the secondary antibody (biotin-labeled goat anti-rabbit IgG) was applied for 30 min at room temperature. Staining was detected with DAB (3,3′-diaminobenzidine tetrahydrochloride) and hematoxylin using a Novolink Polymer Detection Kit (Leica Biosystems). Slides were observed under a light microscope. Specimens from ankles of CIA mice were also stained with Safranin-O/Fast Green to evaluate cartilage lesions and hematoxylin and eosin (H&E) stain to investigate morphology.

**Statistical Analysis.** All quantified results were calculated using GraphPad Prism 5.0 software and are presented as the mean ± standard error (S.E.) of at least three experiments. A statistical comparison of two groups was performed using the Student’s t test. Statistical comparisons of more than two groups were performed using the two-factor analysis of variance with the Bonferroni post hoc test or the Mann–Whitney U test, as appropriate. In all cases, *p < 0.05 was considered statistically significant.

**Reference**

1. Pap, T. & Korb-Pap, A. Cartilage damage in osteoarthritis and rheumatoid arthritis-two unequal siblings. *Nature reviews. Rheumatology* **11**, 606–615, doi:10.1038/nrrheum.2015.95 (2015).
2. Choy, E. H. & Panayi, G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. *The New England journal of medicine* **344**, 907–916, doi:10.1056/NEJM200103223444141207 (2001).
3. Anderson, K. O., Bradley, L. A., Young, L. D., McDaniel, L. K. & Wise, C. M. Rheumatoid arthritis: review of psychological factors related to etiology, occurrence, and treatment. *Psychological bulletin* **98**, 358–387 (1985).
4. Zini, N. et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. *Arthritis research & therapy* **15**, 429 (2014).
5. Spreafico, R. et al. A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment. *Annals of the rheumatic diseases* **71**, 1415–1421 (2012).
6. Murakami, M. & Nishimoto, N. IL-6 inhibitors prevent bone loss and cartilage degeneration in rheumatoid arthritis. *Clinical calcium* **25**, 1851–1857, doi:ClinCa151218511857 (2015).
7. Dancevic, C. M. & McCulloch, D. R. Current and emerging therapeutic strategies for preventing inflammation and aggrecanase-mediated cartilage destruction in arthritis. *Arthritis research & therapy* **16**, 429 (2014).
8. O’Hayre, M., Salanga, C. L., Handel, T. M. & Allen, S. J. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. *Biochem J* **409**, 635–649, doi:10.1042/BJ20071493 (2008).
9. Liu, S. C., Hsu, C. I., Fong, Y. C., Chuang, S. M. & Tang, C. H. CTGF induces monocyte chemoattractant protein-1 expression to enhance monocyte migration in human synovial fibroblasts. *Biochem Biophys Acta 1833*, 1114–1124, doi:10.1016/j.bbamcr.2012.12.014 (2013).
10. Koch, A. E. et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. *J Clin Invest* **90**, 772–779, doi:10.1172/JCI113950 (1992).
11. Yoshida, T. et al. Expression of monocyte chemoattractant and activating factor in rheumatoid arthritis. Regulation of its production in synovial cells by interleukin-1 and tumor necrosis factor. *Arthritis Rheum* **36**, 762–771 (1993).
12. Conti, P., Reale, M., Barbacane, R. C., Castellani, M. L. & Orso, C. Differential production of RANTES and MCP-1 in synovial fluid from the inflamed human knee. *Immunol Lett* **80**, 105–111 (2002).
13. Lai, L. F. CCN1/CTGF: the very model of a modern matricellular protein. *Cellular and molecular life sciences: CMLS* **68**, 3149–3163, doi:10.1007/s00018-011-0779-3 (2011).
14. Chen, C. Y. et al. CCN1 induces osteoclast M production in osteoblasts via integrin-dependent signal pathways. *PloS one* **9**, e106623, doi:10.1371/journal.pone.0106623 (2014).
15. Zhang, Q. et al. A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. *Arthritis Rheum* **60**, 3602–3612, doi:10.1002/art.24999 (2009).
16. Zhu, X. et al. Cyr61 participates in the pathogenesis of rheumatoid arthritis by promoting proIL-1beta production by fibroblast-like synoviocytes through an AKT-dependent NF-kappaB signaling pathway. *Clinical immunology* **157**, 187–197, doi:10.1016/j.clim.2015.02.010 (2015).
17. Chen, C.-Y. et al. CCN1 Promotes VEGF Production in Osteoblasts and Induces Endothelial Progenitor Cell Angiogenesis by Inhibiting miR-126 Expression in Rheumatoid Arthritis. *Journal of Bone and Mineral Research* **32**, 34–45, doi:10.1002/jbmr.2926 (2017).
18. Lisignoli, G. et al. Different chemokines are expressed in human arthritic bone biopsies: IFN-gamma and IL-6 differentially modulate IL-8, MCP-1 and rantes production by arthritic osteoblasts. *Cytokine* **20**, 231–238 (2002).
19. Bai, T., Chen, C. C. & Lau, L. F. Matricellular protein CCN1 activates a proinflammatory genetic program in murine macrophages. *J Immunol* **184**, 3223–3232, doi:10.4049/jimmunol.0902792 (2010).
20. Su, C. M. et al. Osteopontin Promotes Oncostatin M Production in Human Osteoblasts: Implication of Rheumatoid Arthritis Therapy. *Journal of immunology* **195**, 3355–3364, doi:10.4049/jimmunol.1403519 (2015).
21. Bauer, D. et al. Dialyl disulfide inhibits TNFalpha induced CCL2 release through MAPK/ERK and NF-KappaB signaling. *Cytokine* **75**, 117–126, doi:10.1016/j.cyto.2014.12.007 (2015).
22. Liang, B. et al. Angiotensin-(1-7) Attenuates Angiotensin II-Induced ICAM-1, VCAM-1, and MCP-1 Expression via the MAS Receptor Through Suppression of P38 and NF-kappaB Pathways in HUVECs. *Cell Physiol Biochem* **35**, 2472–2482, doi:10.1159/000374047 (2015).
26. Vicente, R., Noel, D., Pers, Y. M., Apparailly, F. & Jorgensen, C. Deregulation and therapeutic potential of microRNAs in arthritic diseases. *Nat Rev Rheumatol* 12, 211–220, doi:10.1038/nrrheum.2015.162 (2016).

27. Dawson, J., Miltz, W., Mir, A. K. & Wiensser, C. Targeting monocyte chemoattractant protein-1 signalling in disease. *Expert Opin Ther Targets* 7, 35–48, doi:10.1517/1742822.7.1.35 (2003).

28. Kawano, S. & Nakamachi, Y. miR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis. *Annals of the rheumatic diseases* 70 Suppl 1, i88–91, doi:10.1136/ard.2010.136669 (2011).

29. Kok, S. H. et al. Simvastatin inhibits cytokine-stimulated Cyr61 expression in osteoblastic cells: a therapeutic benefit for arthritis. *Arthritis Rheum* 63, 1010–1020, doi:10.1002/art.27433 (2011).

30. Yu, Y. et al. The matrix protein CCN1 (CYR61) promotes proliferation, migration and tube formation of endothelial progenitor cells. *Exp Cell Res* 314, 3198–3208, doi:10.1016/j.yexcr.2008.08.001 (2008).

31. Lin, J. et al. Cyr61 induces IL-6 production by fibroblast-like synoviocytes promoting Th17 differentiation in rheumatoid arthritis. *Journal of Immunology* 188, 5776–5784, doi:10.4049/jimmunol.1103201 (2012).

32. Sun, Y. et al. CCN1, a Pro-Inflammatory Factor, Aggravates Psoriasis Skin Lesions by Promoting Keratinocyte Activation. *J Invest Dermatol* 135, 2666–2675, doi:10.1038/jid.2015.231 (2015).

33. Wu, P. et al. Cyr61/CCN1 is involved in the pathogenesis of psoriasis vulgaris via promoting IL-8 production by keratinocytes in a JNK/NE-kappaB pathway. *Clinical immunology* 174, 52–62, doi:10.1016/j.clim.2016.11.003 (2016).

34. Koon, H. W. et al. Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. *Am J Pathol* 173, 400–410, doi:10.2353/ajpath.2008.080222 (2008).

35. Choi, J. S., Kim, K. H. & Lau, L. F. The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. *Mucosal Immunol* 8, 1285–1296, doi:10.1038/mi.2015.19 (2015).

36. Raissadati, A. et al. Systemic overexpression of matricellular protein CCN1 exacerbates obliterative bronchiolitis in murine tracheal allografts. *Transpl Int* 28, 1416–1425, doi:10.1111/tri.12639 (2015).

37. Moon, H. G. et al. CCN1 secretion and cleavage regulate the lung epithelial cell functions after cigarette smoke. *Am J Physiol Lung Cell Mol Physiol* 307, L326–337, doi:10.1152/ajplung.00102.2014 (2014).

38. Moon, H. G., Zheng, Y., An, C. H., Kim, Y. K. & Jin, Y. CCN1 secretion induced by cigarette smoking extracts augments IL-8 release from bronchial epithelial cells. *PloS one* 8, e68199, doi:10.1371/journal.pone.0068199 (2013).

39. Huang, C. Y., Chen, S. Y., Tsai, H. C., Hsu, H. C. & Tang, C. H. Thrombin induces epidermal growth factor receptor transactivation and CCL2 expression in human osteoblasts. *Arthritis Rheum* 64, 3344–3354, doi:10.1002/art.34557 (2012).

40. Su, C. M. et al. Adiponectin Induces Oncostatin M Expression in Osteoblasts through the PI3K/Akt Signaling Pathway. *Int J Mol Sci* 17, doi:10.3390/ijms17101029 (2015).

41. Li, Y.-T. et al. Brief Report: Amelioration of collagen-induced arthritis in mice by lentivirus-mediated silencing of microRNA-223. *Arthritis & Rheumatism* 64, 3240–3245, doi:10.1002/art.34550 (2012).

42. Liu, S., Kiyoi, T., Takemasa, E. & Maeyama, K. Systemic Lentivirus-Mediated Delivery of Short Hairpin RNA Targeting Calcium Release–Activated Calcium Channel 3 as Gene Therapy for Collagen-Induced Arthritis. *The Journal of Immunology* 194, 76–83, doi:10.4049/jimmunol.1401976 (2015).

43. Wang, C. R. et al. intra-articular lentivirus-mediated delivery of galectin-3 shRNA and galectin-1 gene ameliorates collagen-induced arthritis. *Gene Therapy* 17, 1225–1233, doi:10.1038/gt.2010.78 (2010).

44. Latimer, H. R. & Veal, E. A. Peroxiredoxins in Regulation of MAPK Signalling Pathways; Sensors and Barriers to Signal Transduction. *Mol Cells* 39, 40–45, doi:10.14348/molcells.2016.2327 (2016).

45. Bayoumi, A. S. et al. Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease. *Int J Mol Sci* 17, doi:10.3390/ijms17030356 (2016).

46. He, L. & Hannon, G. J. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* 5, 522–531, doi:10.1038/nrg1379 (2004).

47. Wu, M. H. et al. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human choroidonasal cells. *Oncogene* 33, 1725–1735, doi:10.1038/onc.2013.109 (2014).

48. Yu, H. S. et al. Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells. *Biochem Pharmacol* 87, 243–253, doi:10.1016/j.bcp.2013.10.016 (2014).

49. Wang, S. W. et al. CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. *PloS one* 7, e35101, doi:10.1371/journal.pone.0035101 (2012).

50. Chien, S. Y. et al. Interleukin-1beta induces fibroblast growth factor 2 expression and subsequently promotes endothelial progenitor cell angiogenesis in chondrocytes. *Clin Sci (Lond)* 130, 667–681, doi:10.1042/CS20150622 (2016).